A photo showing the logo of Swiss pharmaceutical giant Roche in Basel.
SEBASTIEN BOZON | AFP | Getty Images
Swiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Telavant creates drugs for people suffering from inflammatory and fibrotic diseases, and is in the process of developing a “promising new therapy” for patients with Crohn’s disease, Roche said in a press release.
This is a breaking news story, please check back later for more.